Possibilities of vaccination in the elimination of cervical cancer: achievements and prospect

1. WHO. Human papillomavirus (HPV) and cervical cancer. 24.01.2019. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
2. WHO. WHO Director-general calls for all countries to take action to help end the suffering caused by cervical cancer. May 19, 2018. Available at: https://www.who.int/reproductivehealth/DG_Call-to-Action.pdf
3. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России; 2018. 250 с. [Kaprin A.D., Starinsky V.V., Petrova G.V., ed. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow: MNIOI im. P.A. Herzen – branch of the NWIRTC of the Ministry of Health of Russia; 2018. 250 p. (in Russ.)]
4. Barchuk A., Bespalov A., Huhtala H., Chimed T., Laricheva I., Belyaev A. et al. Breast and cervical cancer incidence and mortality trends in Russia 1980-2013. Cancer Epidemiol. 2018; 55: 73-80.
5. WHO. Vaccine in National Immunization Programme Update June 2019. Available at: https://www.who.int/immunization/monitoring_surveillance/en/
6. Maver P.J., Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. Vaccine. 2018; 36(36): 5416-23.
7. Department of Health and Ageing. Immunise Australia program: human papillomavirus (HPV). February 14, 2013. Available at: http://www.health.gov.au/internet/immunise/publishing.nsf/ Content/immunise-hpv
8. Office of the Prime Minister of Australia. A new vaccine to strengthen the health of young Australians. October 8, 2017. Available at: http://parlinfo.aph.gov au/parlInfo/search/display/display.w3p;query=Id%3A%22media%2F pressrel%2F5562151%22
9. Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. December 4, 2017. Available at: http://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening
10. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Available at: https://kirby.unsw.edu.au/report/hiv-viral-hepatitis-and-sexually-transmissible-infections-australia-annual-surveillance
11. Victorian Cervical Cytology Registry. Statistical Report 2015. Available at: https://www.vccr.org/data-research/statistical-reports/annual-statistical-reports
12. Steben M., Tan Thompson M., Rodier C., Mallette N., Racovitan V., DeAngelis F. et al. A review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J. Obstet. Gynaecol. Can. 2018; 40(12): 1635-45.
13. Garland S.M., Kjaer S.K., Muñoz N., Block S.L., Brown D.R., DiNubile M.J. et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin. Infect. Dis. 2016; 63(4): 519-27.
14. Drolet M., Bénard É., Pérez N., Brisson M.; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; Jun 26. pii: S0140-6736(19)30298-3.
15. Luostarinen T., Apter D., Dillner J., Eriksson T., Harjula K., Natunen K. et al. Vaccination protects against invasive HPV-associated cancers. Int. J. Cancer. 2018; 142(10): 2186-7.
16. Markowitz L.E., Dunne E.F., Saraiya M., Chesson H.W., Curtis C.R., Gee J. et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2014; 63(RR-05): 1-30.
17. Petrosky E., Bocchini J.A. Jr, Hariri S., Chesson H., Curtis C.R., Saraiya M. et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb. Mortal. Wkly Rep. 2015; 64(11): 300-4.
18. Guo F., Cofie L.E., Berenson A.B. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am. J. Prev. Med. 2018; 55(2): 197-204.
19. Hall M.T., Simms K.T., Lew J.B., Smith M.A., Brotherton J.M., Saville M. et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Publ. Health. 2019; 4(1): e19-27.
20. Simms K. Predicting declines in cervical cancer due to vaccination: the global perspective. In: Presented at EUROGIN 2018. Lisbon, Portugal. Abstr. 00570.
21. Kjaer S.K., Nygård M., Dillner J., Brooke Marshall J., Radley D., Li M. et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin. Infect. Dis. 2018; 66(3): 339-45.
22. Kruger-Kjaer S., Nygard M., Dillner J., Munk C., Hansen B., Sigurdardottir L. Et al. In: Presented at EUROGIN 2018. Lisbon, Portugal. Abstr. 00625.
23. WHO. Safety update of HPV vaccines. Available at: http://www.who.int/vaccine_safety/committee/topics/hpv/June_2017/e
24. Краснопольский В.И. и соавт. Эффективность вакцинопрофилактики ВПЧ-ассоциированных заболеваний и рака шейки матки в Московской области. Almanac of Clinical Medicine. 2015; 37: 105-110. [Krasnopol’skiy V.I. et al. Efficacy of vaccine prevention of HPV-associated diseases and cervical cancer in the Moscow region. Almanakh of the clinical medicine. 2015; 37: 105-110 (in Russ.)]
25. Зароченцева Н.В., Белая Ю.М. Опыт реализации программ первичной профилактики заболеваний, вызываемых вирусом папилломы человека, в Московской области. Эпидемиология и Вакцинопрофилактика. 2017; 97(6): 59-65. [Zarochentseva N.V., Belaiya J.M. Experience in the Implementation of Programs for Primary Prevention of Human Papillomavirus-associated Diseases in the Moscow region. Epidemiology and Vaccinal Prevention. 2017: 97(6): 59-65 (in Russ.)]
26. Белоцерковцева Л.Д. и соавт. Внедрение региональной программы вакцинации против ВПЧ-ассоциированных заболеваний в ХМАО-Югре. Педиатрическая фармакология. 2014; 11(4): 29-34 [Belotserkovtseva L.D. et al. Regional Vaccination Program, Vaccination of Adolescents, Quadrivalent Human Papillomavirus Recombinant Vaccine, Cervical Cancer. Pediatricheskaya farmakologiya/Pediatric pharmacology. 2014; 11 (4): 29-34 (in Russ.)]
27. Белоцерковцева Л.Д. и соавт. Репродуктивное поведение подростков и опыт профилактики ВПЧ-ассоциированных заболеваний в ХМАО-Югре. Вопросы гинекологии, акушерства и перинатологии. 2018; 17(1): 100-8. [Belotserkovtseva L.D. et al. Reproductiveehavior of adolescents and an experience of preventing HPV-associated diseases in the Khanty-Mansi Autonomous Okrug-Yugra. Gynecology, Obstetrics and Perinatology. 2018; 17(1): 100-8.(in Russ.)]

Received 06.06.2019

Accepted 21.06.2019